Filing Details

Accession Number:
0001104659-16-163804
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-12-23 18:02:39
Reporting Period:
2016-10-18
Filing Date:
2016-12-23
Accepted Time:
2016-12-23 18:02:39
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1674416 Crispr Therapeutics Ag CRSP () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1354345 Phd J Bradley Bolzon C/O Crispr Therapeutics, Inc.,
200 Sidney Street
Cambridge MA 02139
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-10-24 437,247 $0.00 676,895 No 4 C Indirect See footnote
Common Stock Acquisiton 2016-10-24 3,100,477 $0.00 3,777,372 No 4 C Indirect See footnote
Common Stock Acquisiton 2016-10-24 231,077 $0.00 4,008,449 No 4 C Indirect See footnote
Common Stock Acquisiton 2016-10-24 95,596 $14.00 4,104,045 No 4 P Indirect See footnote
Common Stock Acquisiton 2016-10-24 2,754 $0.00 2,754 No 4 C Indirect See footnote
Common Stock Acquisiton 2016-10-24 19,524 $0.00 22,278 No 4 C Indirect See footnote
Common Stock Acquisiton 2016-10-24 1,454 $0.00 23,732 No 4 C Indirect See footnote
Common Stock Acquisiton 2016-10-24 602 $14.00 24,334 No 4 P Indirect See footnote
Common Stock Acquisiton 2016-10-24 2,210,417 $0.00 2,210,417 No 4 C Indirect See footnote
Common Stock Acquisiton 2016-10-24 173,167 $0.00 2,383,584 No 4 C Indirect See footnote
Common Stock Acquisiton 2016-10-24 60,219 $14.00 2,443,803 No 4 P Indirect See footnote
Common Stock Acquisiton 2016-10-24 66,490 $0.00 66,490 No 4 C Indirect See footnote
Common Stock Acquisiton 2016-10-24 5,210 $0.00 71,700 No 4 C Indirect See footnote
Common Stock Acquisiton 2016-10-24 168,224 $0.00 168,224 No 4 C Indirect See footnote
Common Stock Acquisiton 2016-10-24 13,180 $0.00 181,404 No 4 C Indirect See footnote
Common Stock Acquisiton 2016-10-24 4,583 $14.00 185,987 No 4 P Indirect See footnote
Common Stock Acquisiton 2016-10-24 73,704 $0.00 73,704 No 4 C Indirect See footnote
Common Stock Acquisiton 2016-10-24 5,774 $0.00 79,478 No 4 C Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See footnote
No 4 C Indirect See footnote
No 4 C Indirect See footnote
No 4 P Indirect See footnote
No 4 C Indirect See footnote
No 4 C Indirect See footnote
No 4 C Indirect See footnote
No 4 P Indirect See footnote
No 4 C Indirect See footnote
No 4 C Indirect See footnote
No 4 P Indirect See footnote
No 4 C Indirect See footnote
No 4 C Indirect See footnote
No 4 C Indirect See footnote
No 4 C Indirect See footnote
No 4 P Indirect See footnote
No 4 C Indirect See footnote
No 4 C Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2016-10-18 30,000 $0.00 30,000 $14.00
Common Stock Series A-1 Preferred Shares Disposition 2016-10-24 437,247 $0.00 437,247 $0.00
Common Stock Series A-1 Preferred Shares Disposition 2016-10-24 2,754 $0.00 2,754 $0.00
Common Stock Series A-2 Preferred Shares Disposition 2016-10-24 3,100,477 $0.00 3,100,477 $0.00
Common Stock Series A-2 Preferred Shares Disposition 2016-10-24 19,524 $0.00 19,524 $0.00
Common Stock Series A-3 Preferred Shares Disposition 2016-10-24 2,210,417 $0.00 2,210,417 $0.00
Common Stock Series A-3 Preferred Shares Disposition 2016-10-24 66,490 $0.00 66,490 $0.00
Common Stock Series A-3 Preferred Shares Disposition 2016-10-24 168,224 $0.00 168,224 $0.00
Common Stock Series A-3 Preferred Shares Disposition 2016-10-24 73,704 $0.00 73,704 $0.00
Common Stock Series B Preferred Shares Disposition 2016-10-24 231,077 $0.00 231,077 $0.00
Common Stock Series B Preferred Shares Disposition 2016-10-24 1,454 $0.00 1,454 $0.00
Common Stock Series B Preferred Shares Disposition 2016-10-24 173,167 $0.00 173,167 $0.00
Common Stock Series B Preferred Shares Disposition 2016-10-24 5,210 $0.00 5,210 $0.00
Common Stock Series B Preferred Shares Disposition 2016-10-24 13,180 $0.00 13,180 $0.00
Common Stock Series B Preferred Shares Disposition 2016-10-24 5,774 $0.00 5,774 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
60,000 2026-10-18 No 4 A Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 684,014 Indirect See footnote
Footnotes
  1. Each of the Reporting Person and Thomas Woiwode are managing members of Versant Venture Management, LLC. One-half of these shares were issued to the Reporting Person and one-half of these shares were issued to Mr. Woiwode, in each case, as compensation for service on the Issuer's board of directors. Pursuant to agreements with Versant Venture Management, LLC, the Reporting Person and Mr. Woiwode are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficial own the securities through his interest in Versant Venture Management, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
  2. Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016.
  3. These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
  4. These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
  5. These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
  6. These securities are held of record by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
  7. These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the shares through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein, if any.
  8. These securities are held of record by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
  9. The option grant reported hereby was made to Thomas Woiwode as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person (the grant of which was previously reported by the Reporting Person) and one-half of the reported securities are held by Mr. Woiwode. Pursuant to the agreements described in footnote (1), the Reporting Person and Mr. Woiwode are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in Versant Venture Management, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
  10. This option was granted on October 18, 2016 with respect to 30,000 Common Shares with 100% of the shares vesting in 36 equal monthly installments beginning October 31, 2016.